{"id":76371,"date":"2026-08-24T11:49:24","date_gmt":"2026-08-24T03:49:24","guid":{"rendered":"https:\/\/flcube.com\/?p=76371"},"modified":"2026-08-24T11:49:25","modified_gmt":"2026-08-24T03:49:25","slug":"immuneoncos-imm0306-wins-fda-ind-clearance-for-sle-worlds-first-cd47-cd20-bispecific-in-clinic-enters-u-s","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76371","title":{"rendered":"ImmuneOnco&#8217;s IMM0306 Wins FDA IND Clearance for SLE \u2014 World&#8217;s First CD47\/CD20 Bispecific in Clinic Enters U.S."},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>ImmuneOnco Biopharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1541:HKG\">HKG: 1541<\/a>) announced that its drug <strong>IMM0306<\/strong> has received Investigational New Drug (IND) clearance from the <strong>U.S. FDA<\/strong> to conduct a <strong>Phase Ib\/II clinical trial<\/strong> for the treatment of <strong>systemic lupus erythematosus (SLE)<\/strong> \u2014 marking the U.S. clinical debut of the <strong>world&#8217;s first CD47- and CD20-targeted bispecific molecule<\/strong> to enter clinical development.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Investigational New Drug (IND) clearance<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>IMM0306<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase Ib\/II<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Systemic lupus erythematosus (SLE)<\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>ImmuneOnco Biopharmaceuticals (HKG: 1541)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>21 Aug 2026<\/td><\/tr><tr><td><strong>Novelty<\/strong><\/td><td><strong>First-in-class<\/strong> \u2014 first CD47\/CD20 bispecific molecule in clinical development globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Bispecific molecule independently developed by the Group<\/li>\n\n\n\n<li><strong>Dual Targets:<\/strong> <strong>Cluster of Differentiation 47 (CD47)<\/strong> and <strong>Cluster of Differentiation 20 (CD20)<\/strong><\/li>\n\n\n\n<li><strong>First-in-Class Status:<\/strong> World&#8217;s first CD47- and CD20-targeted bispecific molecule to enter clinical development<\/li>\n\n\n\n<li><strong>Rationale:<\/strong> Combines B-cell depletion via CD20 with CD47 pathway modulation in a single molecule \u2014 a differentiated approach versus standalone anti-CD20 antibodies currently used in autoimmune disease<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-pipeline-across-autoimmune-indications\" class=\"wp-block-heading\">Clinical Pipeline Across Autoimmune Indications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Multiple clinical studies of IMM0306 are currently underway in China across a portfolio of B-cell\u2013driven autoimmune diseases:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Systemic lupus erythematosus (SLE)<\/strong><\/td><td>Multiple studies underway in China; Phase Ib\/II now IND-cleared in the U.S.<\/td><\/tr><tr><td><strong>IgG4-related disease (IgG4-RD)<\/strong><\/td><td>Clinical studies underway in China<\/td><\/tr><tr><td><strong>Primary Sj\u00f6gren&#8217;s syndrome (pSS)<\/strong><\/td><td>Clinical studies underway in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Expansion Milestone:<\/strong> FDA IND clearance extends IMM0306&#8217;s development from China into the U.S., the largest and most commercially consequential market for lupus therapeutics.<\/li>\n\n\n\n<li><strong>First-in-Class Differentiation:<\/strong> As the only CD47\/CD20 bispecific in the clinic worldwide, IMM0306 holds an uncontested mechanistic niche in SLE, where existing targeted options remain limited beyond belimumab and anifrolumab.<\/li>\n\n\n\n<li><strong>Multi-Indication Optionality:<\/strong> Concurrent development across SLE, IgG4-RD and pSS creates several near-term catalyst paths \u2014 a single readout in any indication could validate the platform for the others.<\/li>\n\n\n\n<li><strong>Next Milestones:<\/strong> Investors will watch for first U.S. patient dosing, Phase Ib safety and dose-optimization data, and potential regulatory designations as the program advances.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory timelines and commercial potential of IMM0306. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, and competitive dynamics in autoimmune disease therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082101340_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082101340_c.\"><\/object><a id=\"wp-block-file--media-0457b2f8-0f39-4476-88d4-425f2e60dfa7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082101340_c.pdf\">2026082101340_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082101340_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0457b2f8-0f39-4476-88d4-425f2e60dfa7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ImmuneOnco Biopharmaceuticals (HKG: 1541) announced that its drug IMM0306 has received Investigational New Drug (IND)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,62,1028,229],"class_list":["post-76371","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-hkg-1541","tag-immuneonco-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ImmuneOnco&#039;s IMM0306 Wins FDA IND Clearance for SLE \u2014 World&#039;s First CD47\/CD20 Bispecific in Clinic Enters U.S. - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ImmuneOnco Biopharmaceuticals (HKG: 1541) announced that its drug IMM0306 has received Investigational New Drug (IND) clearance from the U.S. FDA to conduct a Phase Ib\/II clinical trial for the treatment of systemic lupus erythematosus (SLE) \u2014 marking the U.S. clinical debut of the world&#039;s first CD47- and CD20-targeted bispecific molecule to enter clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76371\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmuneOnco&#039;s IMM0306 Wins FDA IND Clearance for SLE \u2014 World&#039;s First CD47\/CD20 Bispecific in Clinic Enters U.S.\" \/>\n<meta property=\"og:description\" content=\"ImmuneOnco Biopharmaceuticals (HKG: 1541) announced that its drug IMM0306 has received Investigational New Drug (IND) clearance from the U.S. FDA to conduct a Phase Ib\/II clinical trial for the treatment of systemic lupus erythematosus (SLE) \u2014 marking the U.S. clinical debut of the world&#039;s first CD47- and CD20-targeted bispecific molecule to enter clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76371\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T03:49:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-24T03:49:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76371#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76371\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ImmuneOnco&#8217;s IMM0306 Wins FDA IND Clearance for SLE \u2014 World&#8217;s First CD47\\\/CD20 Bispecific in Clinic Enters U.S.\",\"datePublished\":\"2026-08-24T03:49:24+00:00\",\"dateModified\":\"2026-08-24T03:49:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76371\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1541\",\"ImmuneOnco Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76371#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76371\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76371\",\"name\":\"ImmuneOnco's IMM0306 Wins FDA IND Clearance for SLE \u2014 World's First CD47\\\/CD20 Bispecific in Clinic Enters U.S. - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-24T03:49:24+00:00\",\"dateModified\":\"2026-08-24T03:49:25+00:00\",\"description\":\"ImmuneOnco Biopharmaceuticals (HKG: 1541) announced that its drug IMM0306 has received Investigational New Drug (IND) clearance from the U.S. FDA to conduct a Phase Ib\\\/II clinical trial for the treatment of systemic lupus erythematosus (SLE) \u2014 marking the U.S. clinical debut of the world's first CD47- and CD20-targeted bispecific molecule to enter clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76371#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76371\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76371#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmuneOnco&#8217;s IMM0306 Wins FDA IND Clearance for SLE \u2014 World&#8217;s First CD47\\\/CD20 Bispecific in Clinic Enters U.S.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ImmuneOnco's IMM0306 Wins FDA IND Clearance for SLE \u2014 World's First CD47\/CD20 Bispecific in Clinic Enters U.S. - Insight, China&#039;s Pharmaceutical Industry","description":"ImmuneOnco Biopharmaceuticals (HKG: 1541) announced that its drug IMM0306 has received Investigational New Drug (IND) clearance from the U.S. FDA to conduct a Phase Ib\/II clinical trial for the treatment of systemic lupus erythematosus (SLE) \u2014 marking the U.S. clinical debut of the world's first CD47- and CD20-targeted bispecific molecule to enter clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76371","og_locale":"en_US","og_type":"article","og_title":"ImmuneOnco's IMM0306 Wins FDA IND Clearance for SLE \u2014 World's First CD47\/CD20 Bispecific in Clinic Enters U.S.","og_description":"ImmuneOnco Biopharmaceuticals (HKG: 1541) announced that its drug IMM0306 has received Investigational New Drug (IND) clearance from the U.S. FDA to conduct a Phase Ib\/II clinical trial for the treatment of systemic lupus erythematosus (SLE) \u2014 marking the U.S. clinical debut of the world's first CD47- and CD20-targeted bispecific molecule to enter clinical development.","og_url":"https:\/\/flcube.com\/?p=76371","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-24T03:49:24+00:00","article_modified_time":"2026-08-24T03:49:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76371#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76371"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ImmuneOnco&#8217;s IMM0306 Wins FDA IND Clearance for SLE \u2014 World&#8217;s First CD47\/CD20 Bispecific in Clinic Enters U.S.","datePublished":"2026-08-24T03:49:24+00:00","dateModified":"2026-08-24T03:49:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76371"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial approval \/ initiation","HKG: 1541","ImmuneOnco Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76371#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76371","url":"https:\/\/flcube.com\/?p=76371","name":"ImmuneOnco's IMM0306 Wins FDA IND Clearance for SLE \u2014 World's First CD47\/CD20 Bispecific in Clinic Enters U.S. - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-24T03:49:24+00:00","dateModified":"2026-08-24T03:49:25+00:00","description":"ImmuneOnco Biopharmaceuticals (HKG: 1541) announced that its drug IMM0306 has received Investigational New Drug (IND) clearance from the U.S. FDA to conduct a Phase Ib\/II clinical trial for the treatment of systemic lupus erythematosus (SLE) \u2014 marking the U.S. clinical debut of the world's first CD47- and CD20-targeted bispecific molecule to enter clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76371#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76371"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76371#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ImmuneOnco&#8217;s IMM0306 Wins FDA IND Clearance for SLE \u2014 World&#8217;s First CD47\/CD20 Bispecific in Clinic Enters U.S."}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76371"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76371\/revisions"}],"predecessor-version":[{"id":76375,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76371\/revisions\/76375"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}